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Abstract.
PURPOSE: Bowel dysfunction, such as constipation and fecal incontinence, has a significant impact on health, activities of
daily living, and quality of life among people with spina bifida. Secondary complications may result from bowel dysfunction and
include urologic dysfunction, loss of skin integrity, shunt (hydrocephalus) function, as well as loss of social opportunities and
employability.
METHODS: Using a consensus building methodology, the guidelines for management of bowel dysfunction in spina bifida were
written by experts in the field of spina bifida and bowel function and care.
RESULTS: The evidence-based guidelines are presented in table format and provide age-specific recommendations to achieve
fecal continence without constipation. Recommended treatments are presented from least to most invasive options. Literature
supporting the recommendations and the interval research published to date is also presented.
CONCLUSION: These guidelines present a standardized approach to management of bowel dysfunction in spina bifida. Bowel
management in children and young adults with spina bifida is limited by variability in clinical practice and paucity of robust
research in neurogenic bowel. Collaborative multi-institutional efforts are needed to overcome research barriers and provide
innovative solutions.
Keywords: Spina bifida, neural tube defects, neurogenic bowel, neurogenic bowel dysfunction, constipation, fecal incontinence,
bowel management

1. Introduction
Bowel dysfunction, such as constipation and fecal
incontinence, have a significant impact on quality of
life and well-being of individuals with spina bifida as
well as their parents [1–5]. This was highlighted in
2019 when the Spina Bifida Association conducted a
survey of adults with and parents of both children and
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adults with spina bifida. When asked about the impact
of bowel incontinence, 50% of parents of children rated
it as their biggest issue. Parents of adults with spina
bifida rated it as their 3rd most important issue, with
48% of them citing it as a “very big issue”. Adults with
spina bifida ranked bowel incontinence as the 2nd most
important issue with 47% citing it as a “very big issue”.
These results highlight the importance of the guidelines
for bowel function and care [6].
Managing bowel function can be one of the biggest
challenges accompanying the diagnosis of spina bifida
and is also one of the most important. In spina bifida,
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the secondary complications from neurogenic bowel
dysfunction extend beyond constipation and fecal incontinence to include urinary incontinence, urinary tract
infections, shunt (hydrocephalus) malfunction, potential for skin breakdown, hemorrhoids, anal fissures, loss
of social and work opportunities, and decreased quality
of life [3,5,7–10]. Proactive, systematic and rational approaches to these problems can lead to continence and
a more functional lifestyle [7,11–17]. Thus, the guidelines were written to emphasize bowel management in
spina bifida to address a specific goal: bowel continence
without constipation.
In spina bifida, the lack of normal nerve function and
subsequent loss of sensory and motor control significantly impact the lower gastrointestinal tract and colorectal function. Slow colonic transit, probable alterations in colorectal motility, abnormal anal sphincter
function, and decreased sensation lead to constipation
and fecal incontinence [15,16]. Attention to these pathophysiologic mechanisms of neurogenic bowel will lead
to a better understanding, increased adherence to treatment, and increased probability of attaining the goal of
continence without constipation. Treatment should be
considered from least to most invasive and the guidelines are intended as a step by step guide to achieve
continence without constipation.
The guidelines are designed to be adaptable to each
individual. Tailoring the treatment to the individual’s
mobility, cognitive development, and underlying medical and social comorbidities is important in the success
of the bowel program [7,11–13,16–19]. These guidelines should be followed with the guidance of a healthcare professional who has expertise in bowel management in spina bifida.
1.1. Guidelines goals and outcomes
The goals and outcomes are based on what is healthy
from a medical standpoint and also on what is desirable from a personal-social standpoint. As can be seen
from the outcomes listed here, the bowel guidelines
are both practical and aspirational in that the authors
believe continence without constipation is possible for
the majority of patients.
For the bowel care guidelines, the following outcomes were identified:
Primary Outcomes (intervene before health effect
occurs)
– Maintenance of social continence as appropriate
for age level
Secondary Outcomes (screen and identify problems
in the earliest stages)

– Maximization of independence with managing
bowel program
– Maximized knowledge and compliance with diet
and bowel program
Tertiary Outcomes (try to improve quality of life
and reduce the symptoms)
– Minimization of constipation

2. Methods
The methodology for writing the guidelines have
been published by Dicianno et al. [20]. The process
included one hundred Spina Bifida experts from around
the world. The work includes 24 topics, including bowel
function and care for people with spina bifida from birth
through adulthood [21].
2.1. Clinical questions that informed the bowel
function and care guidelines
A set of clinical questions was the foundation of the
Bowel Management Guidelines. These clinical questions were used to focus attention on the outcomes or
goals of the guidelines and inform the quidelines. Table 1 shows clinical questions specific to five sequential age groups. These questions informed the research
and writing of the guidelines. There were five clinical
questions that were pertinent to all of the age groups,
which are listed here:
1. What is expected for bowel management at each
stage of life (infancy, toddler, preschool, school
age, teenage & adult)?
2. What are the options for bowel management at
each stage of life?
3. What bowel symptoms should be evaluated by
age?
4. Why is patient satisfaction important in regard to
bowel management?
5. What education relating to bowel management is
necessary for life long positive outcomes?

3. Results
The guidelines for management of bowel dysfunction
in spina bifida are presented in Table 2. Each age group
is represented with consideration given to the potential
variations in their functional abilities. Literature supporting the guidelines of care and the interval research
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Table 1
Clinical questions that informed the bowel function and care guidelines
Age group
(from guidelines)
0–11 months
1–2 years 11 months
3–5 years 11 months
6–12 years 11 months

13–17 years 11 months
18+ years

Clinical questions
– What evidence exists that prevention of constipation in the first year of life improves outcome of bowel
management in later childhood?
– Is there evidence to support the benefit of toilet training a child with Spina Bifida at the same developmental
stage as peers without dysfunction?
– Is there evidence that “habit training,” or forced evacuation with stimulants, such as suppositories or enemas,
increases social continence?
– What is the evidence that the MACE (Malone antegrade continence enema) procedure or continent cecostomy is
an effective form of bowel management in children with refractory incontinence?
– What are the most effective protocols for MACE (ACE) management?
– What is the evidence that electrical stimulation (sacral nerve or intravesicular) provides benefit for increased
bowel continence?
– What support is needed by young adults with Spina Bifida to be successful in maintaining their bowel program?
– Is there evidence that hormonal fluctuations impact continence?
– What impact does pregnancy have on bowel management or on use of a cecostomy or MACE? (Women’s Health
Guidelines)
– Does early chronic constipation impact management of constipation in adult years?
– Is there a change in bowel function later in life that should be addressed with a more aggressive bowel program?
Does menopause result in changes?

Table 2
The guidelines for bowel care and function for people with spina bifida and the citations of supporting evidence
Age group
Guidelines
0–11 months 1. Monitor stool frequency, consistency, and amounts.
2. Monitor stool frequency, consistency, and amounts.
3. Use dietary management, in particular breastfeeding if possible, as breastmilk is easier to
digest and offers better restoration of the microbiome after surgery.
4. Consider dietary management (fiber and fluids) before pharmacologic adjuncts (sennoside),
and/or rectal stimulants (glycerin suppositories) to manage constipation.
5. Use barrier creams to protect perineal area from breakdown as needed.
1–2 years
11 months

3–5 years
11 months

1.
2.
3.
4.

Evidence
[7, 8, 11]
[8, 11–14, 16, 18]
[8, 11–14, 16, 18]
[8, 11–14, 16, 18, 23],
clinical consensus
[11, 17, 24], Integument
(Skin) Guidelines
[8, 10–11, 17–18]
[8, 10–11, 17–18]
[8, 11, 14–15, 18–19]
[8, 11, 14–15, 18–19]

Discuss toilet training and habit training with parents.
Establish goal of working toward bowel continence.
Focus on fiber, fluids, exercise, and timed bowel movements after meals.
Consider two-pronged approach of oral and rectal interventions to meet the goal of bowel
continence without constipation.
5. Use dietary management (fiber and fluids), pharmacologic adjuncts (sennoside, polyethylene [8, 11, 14–15, 18–19]
glycol), and/or rectal stimulants (glycerin, docusate sodium, or bisacodyl suppositories) to
manage constipation and fecal incontinence.
6. Use barrier creams to protect perineal area from breakdown as needed.
[11, 17, 24] Integument
(Skin) Guidelines
7. Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida. [8, 10], clinical consensus
1. Discuss consequences of constipation and bowel incontinence (including shunt malfunction, [3–5, 7, 10, 18]
urinary tract infections (UTIs), skin breakdown, social isolation.
2. Establish the goal of bowel continence and institute the bowel continence program using
[3–5, 7, 10, 18]
guidelines below.
3. Focus on fiber, fluids, exercise, and timed bowel movements after meals.
[8, 11, 14–15, 18–19]
4. Consider two-pronged approach of oral and rectal interventions to meet the goal of bowel
[8, 11, 14–15, 18–19]
continence without constipation.
5. Use dietary management (fiber and fluids), pharmacologic adjuncts (sennoside, polyethylene [8, 11, 14–15, 18–19]
glycol), and/or rectal stimulants (glycerin, docusate sodium, or bisacodyl suppositories) to
manage constipation and fecal incontinence.
6. Use barrier creams to protect perineal area from breakdown as needed.
[11, 17, 24] Integument
(Skin) Guidelines
7. Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida. [8, 10], clinical consensus
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Table 2, continued

Age group
6–12 years,
11 months

Guidelines
1. Discuss consequences of constipation and bowel incontinence (including shunt malfunction,
urinary incontinence, UTIs, skin breakdown, social isolation) and focus on developing
independent management skills.
2. Establish the goal of bowel continence and institute the bowel continence program using
guidelines below.
3. Assist the child with learning how to minimize and manage bowel accidents.
4. Use barrier creams to protect perineal area from breakdown as needed.
5.
6.
7.
8.

9.
10.
13–17 years,
11 months

1.

2.
3.
4.
5.
6.
7.
8.

9.
10.

18+ years

11.
1.

2.
3.
4.
5.
6.
7.
8.

9.
10.
11.

Evidence
[3–5, 7, 10, 18, 23],
Self-Management and
Independence Guidelines
[3–5, 7, 10, 18]

[7, 11, 24, 26]
[11, 17, 24] Integument
(Skin) Guidelines
Keep a bowel habit diary to better understand triggers for incontinence and overall patterning [10–12, 17, 18]
to direct a choice of options for bowel management.
Focus on fiber, fluids, exercise, and timed bowel movements after meals.
[8, 11, 14–15, 18–19]
Consider twofold attack of oral and rectal interventions to meet the goal of bowel continence [8, 11, 14–15, 18–19]
without constipation or fecal incontinence.
Use dietary management (fiber, fiber supplements, and fluids), pharmacologic adjuncts
[8, 11, 14–15, 18–19]
(sennoside, polyethylene glycol), and/or rectal stimulants (glycerin, docusate sodium, or
bisacodyl suppositories) to manage constipation.
Discuss other options for treatment if the above have failed, including cone enema or other
[8, 11, 14–15, 18–19,
transanal irrigation, cecostomy, or MACE.
25–28]
Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida. [8, 10, 11, 19], clinical
consensus
Discuss consequences of constipation and bowel incontinence (including shunt malfunction, [3–5, 7, 10, 18, 23],
urinary incontinence, UTIs, skin breakdown, social isolation) and focus on developing
Self-Management and
independent management skills.
Independence Guidelines
Establish the goal of bowel continence and institute the bowel continence program using
[3–5, 7, 10, 18]
guidelines below.
Assist the child with learning how to minimize and manage bowel accidents.
[7, 11, 24, 26]
Use barrier creams to protect perineal area from breakdown as needed.
[11, 17, 24] Integument
(Skin) Guidelines
Keep a bowel habit diary to better understand triggers for incontinence and overall patterning [10–12, 17, 18]
to direct a choice of options for bowel management.
Focus on fiber, fluids, exercise, and timed bowel movements after meals.
[8, 11, 14–15, 18–19]
Consider twofold attack of oral and rectal interventions to meet the goal of bowel continence [8, 11, 14–15, 18–19]
without constipation or fecal incontinence.
Use dietary management (fiber, fiber supplements, and fluids), pharmacologic adjuncts
[8, 11, 14–15, 18–19]
(sennoside, polyethylene glycol), and/or rectal stimulants (glycerin, docusate sodium, or
bisacodyl suppositories) to manage constipation.
Discuss other options for treatment if the above have failed, including cone enema or other
[8, 11, 14–15, 18–19,
transanal irrigation, cecostomy, or MACE.
25–28]
Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida. [8, 10, 11, 19], clinical
consensus
Access support services for personal care, if needed.
[11–12, 19, 24]
Discuss consequences of constipation and bowel incontinence (including shunt malfunction, [3–5, 7, 10, 18, 23],
urinary incontinence, UTIs, skin breakdown, social isolation) and focus on developing
Self-Management and
independent management skills.
Independence Guidelines
Establish the goal of bowel continence and institute the bowel continence program using
[3–5, 7, 10, 18]
guidelines below.
Assist the child with learning how to minimize and manage bowel accidents.
[7, 11, 24, 26]
Use barrier creams to protect perineal area from breakdown as needed.
[11, 17, 24] Integument
(Skin) Guidelines
Keep a bowel habit diary to better understand triggers for incontinence and overall patterning [10–12, 17, 18]
to direct a choice of options for bowel management.
Focus on fiber, fluids, exercise, and timed bowel movements after meals.
[8, 11, 14–15, 18–19]
Consider twofold attack of oral and rectal interventions to meet the goal of bowel continence [8, 11, 14–15, 18–19]
without constipation or fecal incontinence.
Use dietary management (fiber, fiber supplements, and fluids), pharmacologic adjuncts
[8, 11, 14–15, 18–19]
(sennoside, polyethylene glycol), and/or rectal stimulants (glycerin, docusate sodium, or
bisacodyl suppositories) to manage constipation.
Discuss other options for treatment if the above have failed, including cone enema or other
[8, 11, 14–15, 18–19,
transanal irrigation, cecostomy, or MACE.
25–28]
Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida. [8, 10, 11, 19], clinical
consensus
Access support services for personal care, if needed.
[11–12, 19, 24]
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Fig. 1. Bowel management steps from conservative to higher levels
of intervention are pictured here [19].

published to date is also presented accordingly. Treatment is presented in a stepwise manner from the least to
most invasive options to achieve fecal continence without constipation as shown in Fig. 1 [19]. The guidelines
should be individualized to meet the medical, developmental, and social needs of the child and young adult
with spina bifida [11,19,22].

4. Discussion
Bowel dysfunction in children and young adults with
spina bifida has a significant impact on their quality of
life and social, emotional, and physical well-being [1].
Guidelines for bowel function and care of neurogenic
bowel in spina bifida were developed to provide agespecific recommendations in order to achieve fecal continence without constipation [20]. The bowel program
should be individualized to accommodate for the physical, developmental, medical, and social barriers. Ultimately, the desired outcomes are social continence in
conjunction with education and compliance to foster
independence [21].
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The evaluation and management of bowel dysfunction in children and young adults with spina bifida is
hampered by variability of practice within and between
centers. This variability stems from limited robust clinical, translational, and basic science research in neurogenic bowel in children with spina bifida. Specifically,
there is lack of normative physiologic data of colorectal
function in neurogenic bowel. We must foster collaborations between the disciplines of clinical, basic, and
translational research to better understand the pathophysiological mechanisms that underlie the aberrations
in colorectal transit, motility, and sensation that result
in fecal incontinence.
To accurately assess symptoms of neurogenic bowel
and the impact of treatment interventions, we need reliable and validated questionnaires for children and caretakers. Two such promising questionnaires include the
pediatric Neurogenic Bowel Dysfunction Score [29]
and Adolescent Fecal Incontinence Constipation Symptom Index [30]. However, multi-institutional collaborative efforts are needed to design and execute larger validation studies. Additionally, initiative should be taken
to standardize the use of validated questionnaires across
institutions in future clinical trials.
In conjunction to these guidelines, social and community support as well as resources are recommended
in order to provide all-inclusive care for children with
spina bifida who suffer from bowel dysfunction. Resources, such as at-home bowel tracking, have been
shown to be effective in revealing specific triggers that
hamper the bowel program [11]. Standardized bowel
tracking systems via paper and more importantly via
smart phone application programs may be helpful to
closely monitor and to implement in-time changes to
bowel management. For school aged children, tracking
of bowel movements and continence could be facilitated
by school aids and teachers. The school nurse plays
a vital role in assisting the child to reach educational
goals and manage health concerns [12]. Development of
educational resources for caretakers and teachers would
be a great asset to the current and future guidelines of
care.
4.1. Limitations
Clinical trials evaluating the efficacy of bowel regimens in children with spina bifida are hindered by
variability in clinical practice and specifically nonstandardized definitions of bowel success. Protocols
utilizing algorithmic approaches to bowel management
in children with spina bifida have been shown to be ef-
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fective in ensuring fecal continence; however larger validation studies are needed [11]. Collaboration is needed
between institutions to design large scale randomized
controlled intervention studies with robust methodology to overcome these barriers. This would then allow
us to evaluate the efficacy of different bowel regimens
and design standardized treatment protocols based on
clinical and diagnostic predictors of bowel success. Ultimately, we need to bridge the knowledge gap between
clinical practice, research, and technology in order to
develop innovative predictive modeling of bowel success in the neurogenic bowel of children with spina
bifida.
In summary, bowel management in children and
young adults with spina bifida is challenging and has
significant psychosocial implications for the patient and
caretakers alike. These guidelines provide a proactive,
systematic, and rational approach to management of
bowel dysfunction including fecal incontinence and
constipation. Collaborative multi-institutional efforts
are needed to overcome the research barriers and provide innovative solutions.
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